U.S. markets closed
  • S&P 500

    4,473.75
    -6.95 (-0.16%)
     
  • Dow 30

    34,751.32
    -63.07 (-0.18%)
     
  • Nasdaq

    15,181.92
    +20.39 (+0.13%)
     
  • Russell 2000

    2,232.91
    -1.54 (-0.07%)
     
  • Crude Oil

    72.57
    -0.04 (-0.06%)
     
  • Gold

    1,753.80
    -41.00 (-2.28%)
     
  • Silver

    22.61
    -1.15 (-4.84%)
     
  • EUR/USD

    1.1770
    -0.0056 (-0.47%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • GBP/USD

    1.3794
    -0.0042 (-0.30%)
     
  • USD/JPY

    109.7240
    +0.3640 (+0.33%)
     
  • BTC-USD

    47,604.22
    -627.84 (-1.30%)
     
  • CMC Crypto 200

    1,209.85
    -23.43 (-1.90%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.37 (-0.62%)
     

Abbott Laboratories (NYSE:ABT) Is Looking To Continue Growing Its Returns On Capital

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital.

Return On Capital Employed (ROCE): What is it?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Abbott Laboratories, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.13 = US$8.1b ÷ (US$73b - US$12b) (Based on the trailing twelve months to June 2021).

Therefore, Abbott Laboratories has an ROCE of 13%. On its own, that's a standard return, however it's much better than the 8.2% generated by the Medical Equipment industry.

See our latest analysis for Abbott Laboratories

roce
roce

In the above chart we have measured Abbott Laboratories' prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Abbott Laboratories here for free.

What Can We Tell From Abbott Laboratories' ROCE Trend?

Abbott Laboratories is displaying some positive trends. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 13%. The amount of capital employed has increased too, by 93%. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, a combination that's common among multi-baggers.

The Bottom Line On Abbott Laboratories' ROCE

In summary, it's great to see that Abbott Laboratories can compound returns by consistently reinvesting capital at increasing rates of return, because these are some of the key ingredients of those highly sought after multi-baggers. And a remarkable 196% total return over the last five years tells us that investors are expecting more good things to come in the future. So given the stock has proven it has promising trends, it's worth researching the company further to see if these trends are likely to persist.

On a final note, we've found 2 warning signs for Abbott Laboratories that we think you should be aware of.

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.